2026-07-23T17:50:14Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/183382024-02-19T15:28:12Zcom_20.500.12105_15322com_20.500.12105_2051col_20.500.12105_16927col_20.500.12105_16961col_20.500.12105_16968

00925njm 22002777a 4500 dc Becerra-Tomás, Nerea author Ruiz-Canela, Miguel author Hernández-Alonso, Pablo author Bulló, Mònica author Li, Jun author Guasch-Ferré, Marta author Toledo, Estefanía author Clish, Clary B author Estruch, Ramon author Ros, Emilio author Fitó, Montserrat author Lee, Chih-Hao author Pierce, Kerry author Arós, Fernando author Serra-Majem, Lluís author Liang, Liming author Razquin, Cristina author Gómez-Gracia, Enrique author Martínez-González, Miguel A author Hu, Frank B author Corella, Dolores author Salas-Salvadó, Jordi author 2021-05-11 The increased prevalence of atrial fibrillation (AF) and heart failure (HF) highlights the need to better understand the mechanisms underlying these cardiovascular diseases (CVDs). In the present study, we aimed to evaluate the association between glycolysis-related metabolites and the risk of AF and HF in a Mediterranean population at high risk of CVD. We used two case-control studies nested within the PREDIMED trial. A total of 512 incident AF cases matched to 734 controls, and 334 incident HF cases matched to 508 controls, were included. Plasma metabolites were quantified by using hydrophilic interaction liquid chromatography coupled with high-resolution negative ion mode MS detection. Conditional logistic regression analyses were performed. The results showed no association between baseline plasma glycolysis intermediates and other related metabolites with AF. Only phosphoglycerate was associated with a higher risk of HF (OR for 1 SD increase: 1.28; 95% CI: 1.06, 1.53). The present findings do not support a role of the glycolysis pathway in the pathogenesis of AF. However, the increased risk of HF associated with phosphoglycerate requires further studies. 10.3390/metabo11050306 2218-1989 Metabolites http://hdl.handle.net/10668/17875 34064960 http://hdl.handle.net/20.500.12105/18338 PREDIMED study atrial fibrillation glycolysis heart failure Glycolysis Metabolites and Risk of Atrial Fibrillation and Heart Failure in the PREDIMED Trial.